# Inhaled mRNA Immunotherapy for Patients With Advanced Lung Cancer or Pulmonary Metastatic Solid Tumors

> **NCT07657611** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 60 (estimated)

## Conditions studied

- Neoplasms
- Solid Tumors
- Neoplasm Metastasis

## Interventions

- **BIOLOGICAL:** Inhaled mRNA

## Key facts

- **NCT ID:** NCT07657611
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-10
- **Primary completion:** 2026-12
- **Final completion:** 2029-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07657611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07657611, "Inhaled mRNA Immunotherapy for Patients With Advanced Lung Cancer or Pulmonary Metastatic Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07657611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*